CRESCENT BIOPHARMA, INC.

CBIOSEC EDGAR

Pharmaceutical Preparations(E9)CIK: 1253689

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	—	—	—	—
Research and Development Expense	$14.0M	$20.1M	$47.5M	$44.9M	$47.0M
Selling, General and Administrative Expense	—	—	—	—	—
Operating Expenses	$17.2M	$39.3M	$64.6M	$61.7M	$61.4M
Operating Income (Loss)	-$17.2M	-$39.3M	-$63.4M	-$51.5M	-$61.4M
Nonoperating Income (Expense)	—	$2.4M	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$17.9M	—	—	—	—
Income Tax Expense (Benefit)	$0.00	—	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$35.6M	$45.3M	$51.8M	$94.3M	$142.8M
Assets, Current	$34.8M	$43.8M	$50.7M	$90.8M	$138.3M
Cash and Cash Equivalents, at Carrying Value	$34.8M	$41.8M	$47.9M	$90.3M	$137.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$0.00	—	—	—	—
Liabilities	$47.1M	$6.9M	$8.9M	$12.7M	$14.6M
Liabilities, Current	$9.6M	$6.8M	$8.9M	$11.8M	$12.4M
Accounts Payable, Current	—	$868.1K	$970.2K	$2.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$6.3M	-$34.9M	-$57.5M	-$39.2M	-$52.0M
Net Cash Provided by (Used in) Investing Activities	$0.00	-$21.4K	-$14.9K	-$68.5K	-$144.9K
Net Cash Provided by (Used in) Financing Activities	$41.0M	$28.8M	$10.7M	$18.1M	$412.9K
Payments to Acquire Property, Plant, and Equipment	$0.00	$21.4K	$14.9K	$68.5K	$144.9K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)